Navigation Links
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
Date:5/8/2013

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding:  the Special Protocol Assessment, or SPA, and the protocol for the Contrave® cardiovascular outcomes trial, or Light Study; the potential for, and timing of, the accrual and adjudication of MACE; the expected retention rate for patients in the Light Study; the probability of success of the Light Study; the potential for, and timing of, resubmission and approval of a NDA for Contrave based on interim results of the Light Study; the possibility of resubmitting the Contrave NDA with the independent DMC report on the interim analysis and without the clinical study report for the interim analysis; the potential to accelerate the timing of the review of the Contrave NDA; the safety and effectiveness of Contrave; the potential for past Contrave clinical trials to predict the outcome of future Contrave clinical trials; the potential to enter into a collaborative partnership to fund Phase III development and, if approved, commercialization of Empatic™; the potential for the FDA to approve an NDA for Empatic without requiring data from a cardiovascular outcomes trial in addition to the data obtained from the Light Study; and the use of pharmacotherapy to treat obesity. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orex
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
7. Fate Therapeutics Strengthens Its iPSC Platform
8. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
11. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 According to Jeff Howell, Partner ... ITRA Global, new development in Downtown Toronto is expanding ... approving another 755 storeys of new development last week ... will be dominating the Toronto skyline for the foreseeable ... unquenchable thirst for new development. , As the Toronto ...
(Date:9/16/2014)... September 16, 2014 RENU 28, the world's ... became available for purchase in Australia and New Zealand ... tour beginning September 16th. The tour will make stops in ... Bundaberg on the 18th, Sydney on the 20th, and Melbourne ... Australia and New Zealand and to educate people about the ...
(Date:9/15/2014)... UPTON, NYHeat drives classical phase transitionsthink solid, ... happen when the temperature drops. If phase ... where quantum mechanics reigns, subtle fluctuations can ... from the U.S. Department of Energy,s Brookhaven ... explored this frigid landscape of absolute zero ...
(Date:9/15/2014)... 2014   Global Science & Technology, Inc. ... and services for satellite and weather systems, was ... Services (OASIS) from the General Services Administration (GSA) ... provide the government best-value solutions for complex professional ... in Pool 4. The OASIS SB award has ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTC Bulletin Board: ... 7,850,970, entitled "Inhibitors of Serine Protease Activity and Their Use ... issued by the United States Patent and Trademark Office (USPTO) ... New Patent is part of the technology licensed to Omni ...
... new method of child and maternal nutrition could prevent a ... up to 160 million brain cells in each person over ... related to aging and cancer. Most people are ... contaminated with a radioactive material from the air known as ...
... YORK, Jan. 4, 2011 Reportlinker.com announces ... available in its catalogue: ... Strategies for Suppliers,>The 2011 Coagulation Testing Market: ... Market Expansion Strategies for Suppliers ...
Cached Biology Technology:Omni Bio Pharmaceutical Awarded Patent for Preventing Anthrax Infection 2Omni Bio Pharmaceutical Awarded Patent for Preventing Anthrax Infection 3New Method of Nutrition to Permanently Protect Brain Cells from Genetic Damage 2Reportlinker Adds The 2011 Coagulation Testing Market: US, Europe, Japan Emerging Business Opportunities and Market Expansion Strategies for Suppliers 2
(Date:9/15/2014)... leading coral reef ecologists fears that reef biodiversity may ... that we once thought. , In an international study ... of Excellence for Coral Reef Studies (Coral CoE) says ... species within reef ecosystems. , In coral reefs, just ... that keep the ecosystem safe and functioning. , ...
(Date:9/15/2014)... for the first 500 million years after it formed ... complete with oceans, continents and active crustal plates. , ... the Hadean, has gained substantial new support from the ... than 4 billion years ago with those formed contemporaneously ... geological analog for early Earth. , The study was ...
(Date:9/15/2014)... transplanted combinations of wild, domesticated, and domesticated-wild ... new environments found that within 5 to ... genes from wild populations that hybridized with ... study provides evidence that natural selection, ... hybridized populations experience as a result of ...
Breaking Biology News(10 mins):Specialized species critical for reefs 2Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... a half-dozen palladium- and iron-based catalysts for cleaning up the ... TCE far faster than iron -- up to a billion ... in a new study in the August issue of the ... trichloroethene, is a widely used chemical degreaser and solvent that,s ...
... Six, the world leader in synthetic diamond supermaterials, ... Departments of Chemistry and Physics, have demonstrated the ... metal-like boron-doped synthetic diamond. The research shows that ... retaining the full strength and durability of its ...
... NANG, VietnamU.S. scientists and Vietnamese researchers will discuss coastal ... the R/V Roger Revelle , an auxiliary general ... port call in the city of Da Nang. ... operated by the Scripps Institution of Oceanography, the advanced ...
Cached Biology News:Palladium-gold nanoparticles clean TCE a billion times faster than iron filings 2Synthetic diamond steps closer to next generation of high performance electrochemical applications 2Synthetic diamond steps closer to next generation of high performance electrochemical applications 3US research vessel winds down visit to Vietnam as part of joint oceanographic research program 2
ANTI ALPHA FSH:B...
Collected from normal, healthy animals in carefully maintained standing herds of US orgin. Pricing: $45/unit for 1 - 10 units...
Normal donkey serum collected from healthy normal donkeys....
acridine orange 10-nonyl bromide (nonyl acridine orange)...
Biology Products: